NCT05586581View on ClinicalTrials.gov

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions
HIV Associated Neurocognitive DisorderHIV DementiaHIV EncephalitisHealthy
Interventions
DRUG

SV2A PET

SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain

DRUG

TSPO PET

TSPO PET scan with radiotracer \[11C\]PBR28 for imaging of neuroimmune status

Trial Locations (1)

06510

RECRUITING

Yale School of Medicne, Neuro ID Research Program, New Haven

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Yale University

OTHER